Aspirin and clopidogrel resistance: methodological challenges and opportunities

Armen Yuri Gasparyan
  • Vascular Health and Risk Management, March 2010, Dove Medical Press
  • DOI: 10.2147/vhrm.s9087

Aspirin and clopidogrel resistance

What is it about?

Abstract: Antiplatelet drug resistance is one of the urgent issues in current cardiovascular medicine. Many platelet function tests have been used to define responsiveness of patients with cardiovascular disease to aspirin and clopidogrel. In most studies, cut-off values of platelet function tests for defining responsiveness to antiplatelets were chosen arbitrarily. Different tests provided wide-ranging figures of the prevalence of aspirin and clopidogrel resistance, suggesting poor correlation between currently available platelet function tests. Measurement of platelet size seems to be a promising approach for monitoring antiplatelet drug therapy. This commentary highlights some limitations of studies on aspirin and clopidogrel resistance in patients undergoing coronary interventions.

Why is it important?

Highlights the need of comprehensive evaluation of platelet function in patients on antiplatelets.


Associate Professor Armen Yuri Gasparyan (Author)
Dudley Group NHS Foundation Trust, Teaching Trust of University of Birmingham

Helps to properly employ and interpret platelet function tests.

The following have contributed to this page: Associate Professor Armen Yuri Gasparyan